Amy McMichael, MD

Articles by Amy McMichael, MD

Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions.

Latest Updated Articles



    Brand Logo

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    © 2025 MJH Life Sciences®

    All rights reserved.

    Secondary Brand Logo